Theorem Adds RadMD to its Roster of Strategic Alliances
News Aug 16, 2013
Theorem Clinical Research has announced the addition of RadMD, a cutting-edge medical imaging expertise company, to its roster of strategic alliances.
“These kinds of alliances allow us to extend our capabilities to offer a greater depth and spectrum of services to our clients,” said D. Lee Spurgin Jr., Ph.D., Theorem senior vice president and general manager of medical device and diagnostic development.
Spurgin continued, “When we work with partners that we already know and trust, we feel our clients get a better end result.”
With the increasing utilization of imaging in clinical research, there has been a greater demand for expertise on the use of medical imaging in clinical trials.
RadMD offers unique services centered solely on the use of imaging in trials. They provide a consultative approach to implementing medical imaging endpoints based on extensive experience in the pharmaceutical development of both diagnostic and therapeutic drugs.
RadMD’s services include expertise in constructing customized medical imaging solutions, a unique worldwide network of more than 600 physicians and medical imaging experts available for independent image evaluations or “blinded reads”, regulatory strategy, imaging endpoint justification and extensive imaging training capabilities.
“We are excited to be able to bring our imaging expertise in clinical development to Theorem’s clientele, and look forward to working together to develop innovative products for our mutual customers and patients,” said Doug Stefanelli RadMD COO and executive vice president.
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019